Lactadherin inhibits enzyme complexes of blood coagulation by competing for phospholipid-binding sites

Blood

Volumn 101, Issue 7, 2003, Pages 2628-2636

  Shi, Jialan ^b   Gilbert, Gary E ^a  

^a VA BOSTON HEALTHCARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8A; BLOOD CLOTTING FACTOR 9A; ENZYME; GLYCOPROTEIN; LACTADHERIN; LIPOCORTIN 5; PHOSPHATIDYLSERINE; PHOSPHOLIPID; THROMBOPLASTIN; UNCLASSIFIED DRUG; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 7A; MEMBRANE ANTIGEN; MFGE8 PROTEIN, HUMAN; MILK PROTEIN;

ARTICLE; BINDING SITE; BLOOD CLOTTING; CORRELATION ANALYSIS; MEMBRANE BINDING; PRIORITY JOURNAL; PROTEIN BINDING; PROTHROMBIN TIME; SEQUENCE HOMOLOGY; ANIMAL; BINDING COMPETITION; CATTLE; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; METABOLISM;

ANIMALS; ANTICOAGULANTS; ANTIGENS, SURFACE; BINDING SITES; BINDING, COMPETITIVE; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; CATTLE; FACTOR VIIA; FACTOR VIII; HUMANS; MILK PROTEINS; PHOSPHOLIPIDS; PROTEIN BINDING; THROMBOPLASTIN;

EID: 0038107373     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-07-1951     Document Type: Article

References (57)

1. Hvarregaard J, Andersen MH, Berglund L, Rasmussen JT, Petersen TE. Characterization of glycoprotein PAS-6/7 from membranes of bovine milk fat globules. Eur J Biochem. 1996;240:628-636.
2. Stubbs J, Lekutis C, Singer K, et al. cDNA cloning of a mouse mammary epithelial cell surface protein reveals the existence of epidemal growth factor-like domains linked to factor VIII-like sequences. Proc Natl Acad Sci U S A. 1990;87:8417-8421.
3. Couto JR, Taylor MR, Godwin SG, Ceriani RL, Peterson JA. Cloning and sequence analysis of human breast epithelial antigen BA46 reveals an RGD cell adhesion sequence presented on an epidermal growth factor-like domain. DNA Cell Biol. 1996;15:281-286.
4. 5 integrin and anionic phospholipids through two domains. Biochemistry. 1997;36:5441-5446.
5. Taylor MR, Couto JR, Scallan CD, Ceriani RL, Peterson JA. Lactadherin (formerly BA46), a membrane-associated glycoprotein expressed in human milk and breast carcinomas, promotes Arg-Gly-Asp (RGD)-dependent cell adhesion. DNA Cell Biol. 1997;16:861-869.
6. Andersen MH, Graversen H, Fedosov SN, Petersen TE, Rasmussen JT. Functional analyses of two cellular binding domains of bovine lactadherin. Biochemistry. 2000;39:6200-6206.
7. Butler JE, Pringnitz DJ, Martens CL, Crouch N. Bovine-associated mucoprotein, I: distribution among adult and fetal bovine tissues and body fluids. Differentiation. 1980;17:31-40.
8. Newburg DS, Peterson JA, Ruiz-Palacios GM, et al. Role of human-milk lactadherin in protection against symptomatic rotavirus infection. Lancet. 1998;351:1160-1164.
9. Peterson JA, Couto JR, Taylor MR, Ceriani RL. Selection of tumor-specific epitopes on target antigens for radioimmunotherapy of breast cancer. Cancer Res. 1995;55(suppl):5847s-5851s.
10. Haggqvist B, Naslund J, Sletten K, et al. Medin: an integral fragment of aortic smooth muscle cell-produced lactadherin forms the most common human amyloid. Proc Natl Acad Sci U S A. 1999;96:8669-8674.
11. Ensslin M, Calvete JJ, Thole HH, et al. Identification by affinity chromatography of boar sperm membrane-associated proteins bound to immobilized porcine zona pellucida: mapping of the phosphorylethanolamine-binding region of spermadhesin AWN. Biol Chem Hoppe Seyler. 1995;376:733-738.
12. Arai M, Scandella D, Hoyer L. Molecular basis of factor VIII inhibition by human antibodies: antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid. J Clin Invest. 1989:83:1978-1984.
13. Foster PA, Fulcher CA, Houghten RA, Zimmerman TS. Synthetic factor VIII peptides with amino acid sequences contained within the C2 domain of factor VIII inhibit factor VIII binding to phosphatidylserine. Blood. 1990;75:1999-2004.
14. Ortel T, Devore-Carter D, Quinn-Allen M, Kane W. Deletion analysis of recombinant human factor V: evidence for a phosphatidylserine binding site in the second C-type domain. J Biol Chem. 1992;267:4189-4198.
15. Gilbert GE, Furie BC, Furie B. Binding of human factor VIII to phospholipid vesicles. J Biol Chem. 1990;265:815-822.
16. Gilbert GE, Drinkwater D, Barter S, Clouse SB. Specificity of phosphatidylserine-containing membrane binding sites for factor VIII: studies with model membranes supported by glass microspheres (lipospheres). J Biol Chem. 1992;267:15861-15868.
17. Gilbert GE, Drinkwater D. Specific membrane binding of factor VIII is mediated by O-phospho-L-serine. a moiety of phosphatidylserine. Biochemistry. 1993;32:9577-9585.
18. Comfurius P, Smeets EF, Willems GM, Bevers EM, Zwaal RFA. Assembly of the prothrombinase complex on lipid vesicles depends on the stereochemical configuration of the polar headgroup of phosphatidylserine. Biochemistry. 1994;33:10319-10324.
19. Gilbert GE, Arena AA. Phosphatidylethanolamine induces high affinity binding sites for factor VIII on membranes containing phosphatidyl-L-serine. J Biol Chem. 1995;270:18500-18505.
20. Gilbert GE, Arena AA. Unsaturated phospholipid acyl chains are required to constitute membrane binding sites for factor VIII. Biochemistry. 1998;37:13526-13535.
21. Pratt KP, Shen BW, Takeshima K, et al. Structure of the C2 domain of human factor VIII at 1.5 angstrom resolution. Nature. 1999;402:439-442.
22. Macedo-Ribeiro S, Bode W, Huber R, et al. Crystal structures of the membrane-binding C2 domain of human coagulation factor V. Nature. 1999;402:434-439.
23. Kim SW, Quinn-Allen MA, Camp JT, et al. Identification of functionally important amino acid residues within the C2-domain of human factor V using alanine-scanning mutagenesis. Biochemistry. 2000;39:1951-1958.
24. Gilbert GE, Kaufman RJ, Arena AA, Miao H, Pipe SW. Four hydrophobic amino acids in the factor VIII C2 domain are constituents of the membrane-binding and von Willebrand factor-binding motif. J Biol Chem. 2002;277:6374-6381.
25. Peterson JA, Patton S, Hamosh M. Glycoproteins of the human milk fat globule in the protection of the breast-fed infant against infections. Biol Neonate. 1998;74:143-162.
26. Tait JF, Gibson D, Fujikawa K. Phospholipid binding properties of human placental anticoagulant protein-1, a member of the lipocortin family. J Biol Chem. 1989;264:7944-7949.
27. Crompton MR, Moss SE, Crumpton MJ. Diversity in the lipocortin/calpactin family. Cell. 1988;55:1-3.
28. Swairjo MA, Concha NO, Kaetzet MA, Dedman JR, Seaton BA. Ca2+-bridging mechanism and phospholipid head group recognition in the membrane-binding protein annexin V. Nat Struct Biol. 1995;2:968-974.
29. Tait JF, Sakata MS, McMullen BA, et al. Placental anticoagulant proteins: isolation and comparative characterization of four members of the lipocortin family. Biochemistry. 1988;27:6268-6276.
30. Gilbert GE, Arena AA. Activation of the factor VIIIa-factor IXa enzyme complex of blood coagulation by membranes containing phosphatidyl-L-serine. J Biol Chem. 1996;271:11120-11125.
31. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 1965;13:238-252.
32. Johnson SM, Bangham AD, Hill MW, Korn ED. Single bilayer liposomes. Biochim Biophys Acta. 1971;233:820-826.
33. Hope MJ, Bally MB, Webb G, Cullis PR. Production of large unilamellar vesicles by a rapid extrusion procedure: characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim Biophys Acta. 1985;812:55-65.
34. Chen P, Toribara T, Warner H. Microdetermination of phosphorus. Anal Chem. 1956;28:1756-1758.
35. Neuenschwander PF, Morrissey JH. Deletion of the membrane anchoring region of tissue factor abolishes autoactivation of factor VII but not co-factor function: analysis of a mutant with a selective deficiency in activity. J Biol Chem. 1992;267:14477-14482.
36. Lollar P, Fass DN. Inhibition of activated porcine factor IX by dansyl-glutamyl-glycyl-arginyl-chloromethylketone. Arch Biochem Biophys. 1984;233:438-446.
37. Gilbert GE, Sims PJ, Wiedmer T, et al. Platelet-derived microparticles express high affinity receptors for factor VIII. J Biol Chem. 1991;266:17261-17268.
38. Govers-Riemslag JW, Janssen MP, Zwaal RF, Rosing J. Prothrombin activation on dioleoylphosphatidylcholine membranes. Eur J Biochem. 1994;220:131-138.
39. Andree HA, Stuart MC, Hermens WT, et al. Clustering of lipid-bound annexin V may explain its anticoagulant effect. J Biol Chem. 1992;267:17907-17912.
40. Huang C, Mason J. Geometric packing constraints in egg phosphatidylcholine vesicles. Proc Natl Acad Sci U S A. 1978;75:308-310.
41. Andree H, Reutellngsperger C, Hauptmann R, et al. Binding of vascular anticoagulant α (VACα) to planar phospholipid bilayers. J Biol Chem. 1990;265:4923-4928.
42. Ueno M, Tanford C, Reynolds JA. Phospholipid vesicle formation using nonionic detergents with low monomer solubility: kinetic factors determine vesicle size and permeability. Biochemistry. 1984;23:3070-3076.
43. Mann KG, Nesheim ME, Church WR, Haley P, Krishnaswamy S. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood. 1990;76:1-16.
44. Freyssinet JM, Gauchy J, Cazenave JP. The effect of phospholipids on the activation of protein C by the human thrombin-thrombomodulin complex. Biochem J. 1986;238:151-157.
45. Suzuki K, Stenflo J, Dahlback B, Teodorsson B. Inactivation of human coagulation factor V by activated protein C. J Biol Chem. 1983;258:1914-1920.
46. Connor J, Schroit A. Transbilayer movement of phosphatidylserine in erythrocytes: inhibition of transport and preferential labeling of a 31000-dalton protein by sulfhydryl reactive reagents. Biochemistry. 1988;27:848-851.
47. Connor J, Bucana C, Fidler IJ, Schroit AJ. Differentiation-dependent expression of phosphatidylserine in mammalian plasma membranes: quantitative assessment of outer-leaflet lipid by prothrombinase complex formation. Proc Natl Acad Sci U S A. 1989;86:3184-3188.
48. Fadok VA, Voelker DR, Campbell PA, et al. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol. 1992;148:2207-2216.
49. Bevers E, Comfurius P, Zwaal R. Changes in membrane phospholipid distribution during platelet activation. Biochim Biophys Acta. 1983;736:57-66.
50. van Heerde WL, Poort S, van 't Veer C, Reutelingsperger CP, de Groot PG. Binding of recombinant annexin V to endothelial cells: effect of annexin V binding on endothelial-cell-mediated thrombin formation. Biochem J. 1994;302(pt 1):305-312.
51. London F, Ahmad SS, Walsh PN. Annexin V inhibition of factor IXa-catalyzed factor X activation on human platelets and on negatively-charged phospholipid vesicles. Biochemistry. 1996;35:16886-16897.
52. Nimpf J, Bevers EM, Bomans PH, et al. Prothrombinase activity of human platelets is inhibited by beta 2-glycoprotein-I. Biochim Biophys Acta. 1986;884:142-149.
53. Mori T, Takeya H, Nishioka J, Gabazza EC, Suzuki K. beta 2-Glycoprotein I modulates the anticoagulant activity of activated protein C on the phospholipid surface. Thromb Haemost. 1996;75:49-55.
54. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A. 1990;87:4120-4124.
55. Takeya H, Mori T, Gabazza EC, et al. Anti-beta2-glycoprotein I (beta2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the beta2GPI binding to phospholipids. J Clin Invest. 1997;99:2260-2268.
56. Bancsi LF, van der Linden IK, Bertina RM. Beta 2-glycoprotein I deficiency and the risk of thrombosis, Thromb Haemost. 1992;67:649-653.
57. Ceriani RL, Sasaki M, Sussman H, Wara WM, Blank EW, Circulating human mammary epithelial antigens in breast cancer. Proc Natl Acad Sci U S A. 1982;79:5420-5424.